{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:00:11Z","timestamp":1778644811861,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Grant 106665"],"award-info":[{"award-number":["Grant 106665"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11010-020-03777-9","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:02:30Z","timestamp":1591959750000},"page":"165-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Resveratrol attenuates angiotensin II-induced cellular hypertrophy through the inhibition of CYP1B1 and the cardiotoxic mid-chain HETE metabolites"],"prefix":"10.1007","volume":"471","author":[{"given":"Sherif M.","family":"Shoieb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-0400","authenticated-orcid":false,"given":"Ayman O. S.","family":"El-Kadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"3777_CR1","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1113\/JP271161","volume":"593","author":"AN Kavazis","year":"2015","unstructured":"Kavazis AN (2015) Pathological vs. physiological cardiac hypertrophy. J Physiol 593:3767","journal-title":"J Physiol"},{"key":"3777_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu I, Minamino T (2016) Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 97:245\u2013262","journal-title":"J Mol Cell Cardiol"},{"key":"3777_CR3","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","volume":"390","author":"M Metra","year":"2017","unstructured":"Metra M, Teerlink JR (2017) Heart failure. Lancet 390:1981\u20131995","journal-title":"Lancet"},{"key":"3777_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/jcm5070062","volume":"5","author":"A Inamdar","year":"2016","unstructured":"Inamdar A, Inamdar A (2016) Heart failure: diagnosis, management and utilization. J Clin Med 5:62. https:\/\/doi.org\/10.3390\/jcm5070062","journal-title":"J Clin Med"},{"key":"3777_CR5","unstructured":"2016 Report on the Health of Canadians"},{"key":"3777_CR6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1111\/jcmm.14129","volume":"23","author":"L Zhu","year":"2019","unstructured":"Zhu L, Li C, Liu Q et al (2019) Molecular biomarkers in cardiac hypertrophy. J Cell Mol Med 23:1671\u20131677","journal-title":"J Cell Mol Med"},{"key":"3777_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00021.2001","volume":"82","author":"RJ Roman","year":"2002","unstructured":"Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131\u2013185. https:\/\/doi.org\/10.1152\/physrev.00021.2001","journal-title":"Physiol Rev"},{"key":"3777_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1124\/dmd.118.082073","volume":"46","author":"SM Shoieb","year":"2018","unstructured":"Shoieb SM, El-Kadi AOS (2018) S-enantiomer of 19-hydroxyeicosatetraenoic acid preferentially protects against angiotensin II-induced cardiac hypertrophy. Drug Metab Dispos 46:1157\u20131168. https:\/\/doi.org\/10.1124\/dmd.118.082073","journal-title":"Drug Metab Dispos"},{"key":"3777_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cardiores.2005.06.007","volume":"68","author":"G Gross","year":"2005","unstructured":"Gross G, Falck J, Gross E et al (2005) Cytochrome and arachidonic acid metabolites: role in myocardial ischemia\/reperfusion injury revisited. Cardiovasc Res 68:18\u201325. https:\/\/doi.org\/10.1016\/j.cardiores.2005.06.007","journal-title":"Cardiovasc Res"},{"key":"3777_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1161\/HYPERTENSIONAHA.110.154518","volume":"56","author":"BL Jennings","year":"2010","unstructured":"Jennings BL, Sahan-Firat S, Estes AM et al (2010) Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertens (Dallas, Tex, 1979) 56:667\u2013674. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.154518","journal-title":"Hypertens (Dallas, Tex, 1979)"},{"key":"3777_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1124\/dmd.118.084657","volume":"47","author":"SM Shoieb","year":"2019","unstructured":"Shoieb SM, El-Sherbeni AA, El-Kadi AOS (2019) Identification of 19-(S\/R )hydroxyeicosatetraenoic acid as the first endogenous noncompetitive inhibitor of cytochrome P450 1B1 with enantioselective activity. Drug Metab Dispos 47:67\u201370. https:\/\/doi.org\/10.1124\/dmd.118.084657","journal-title":"Drug Metab Dispos"},{"key":"3777_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10557-014-6510-4","volume":"28","author":"BL Jennings","year":"2014","unstructured":"Jennings BL, Montanez DE, May ME et al (2014) Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther 28:145\u2013161. https:\/\/doi.org\/10.1007\/s10557-014-6510-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"3777_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/HYPERTENSIONAHA.115.06427","volume":"67","author":"CY Song","year":"2016","unstructured":"Song CY, Ghafoor K, Ghafoor HU et al (2016) Cytochrome P450 1B1 contributes to the development of atherosclerosis and hypertension in apolipoprotein E-deficient mice. Hypertens 67:206\u2013213. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06427","journal-title":"Hypertens"},{"key":"3777_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20164068","author":"G Anderson","year":"2019","unstructured":"Anderson G, Mazzoccoli G (2019) Left ventricular hypertrophy: roles of mitochondria CYP1B1 and melatonergic pathways in co-ordinatingwider pathophysiology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20164068","journal-title":"Int J Mol Sci"},{"key":"3777_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.phrs.2015.12.016","volume":"105","author":"ZH Maayah","year":"2016","unstructured":"Maayah ZH, Althurwi HN, Abdelhamid G et al (2016) CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacol Res 105:28\u201343. https:\/\/doi.org\/10.1016\/j.phrs.2015.12.016","journal-title":"Pharmacol Res"},{"key":"3777_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yjmcc.2018.10.023","volume":"125","author":"N Matsumura","year":"2018","unstructured":"Matsumura N, Takahara S, Maayah ZH et al (2018) Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites. J Mol Cell Cardiol 125:162\u2013173. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.10.023","journal-title":"J Mol Cell Cardiol"},{"key":"3777_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/FJC.0000000000000494","volume":"70","author":"S Elkhatali","year":"2017","unstructured":"Elkhatali S, Maayah ZH, El-Sherbeni AA et al (2017) Inhibition of mid-chain HETEs protects against angiotensin II-induced cardiac hypertrophy. J Cardiovasc Pharmacol 70:16\u201324. https:\/\/doi.org\/10.1097\/FJC.0000000000000494","journal-title":"J Cardiovasc Pharmacol"},{"key":"3777_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010063","author":"E Cione","year":"2019","unstructured":"Cione E, La Torre C, Cannataro R et al (2019) Quercetin, epigallocatechin gallate, curcumin, and resveratrol: from dietary sources to human microRNA modulation. Molecules. https:\/\/doi.org\/10.3390\/molecules25010063","journal-title":"Molecules"},{"key":"3777_CR19","doi-asserted-by":"publisher","DOI":"10.33390\/nu8050250","author":"D Bonnefont-Rousselot","year":"2016","unstructured":"Bonnefont-Rousselot D (2016) Resveratrol and cardiovascular diseases. Nutrients. https:\/\/doi.org\/10.33390\/nu8050250","journal-title":"Nutrients"},{"key":"3777_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030627","author":"IY Abdelgawad","year":"2019","unstructured":"Abdelgawad IY, Grant MKO, Zordoky BN (2019) Leveraging the cardio-protective and anticancer properties of resveratrol in cardio-oncology. Nutrients. https:\/\/doi.org\/10.3390\/nu11030627","journal-title":"Nutrients"},{"key":"3777_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200700202","author":"R Mikstacka","year":"2008","unstructured":"Mikstacka R, Baer-Dubowska W, Wieczorek M, Sobiak S (2008) Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Mol Nutr Food Res. https:\/\/doi.org\/10.1002\/mnfr.200700202","journal-title":"Mol Nutr Food Res"},{"key":"3777_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/toxsci\/kfp079","volume":"110","author":"SR Beedanagari","year":"2009","unstructured":"Beedanagari SR, Bebenek I, Bui P, Hankinson O (2009) Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci 110:61\u201367. https:\/\/doi.org\/10.1093\/toxsci\/kfp079","journal-title":"Toxicol Sci"},{"key":"3777_CR23","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/carcin\/bgh183","volume":"25","author":"Z-H Chen","year":"2004","unstructured":"Chen Z-H (2004) Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 25:2005\u20132013. https:\/\/doi.org\/10.1093\/carcin\/bgh183","journal-title":"Carcinogenesis"},{"key":"3777_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900418","author":"LX Zou","year":"2019","unstructured":"Zou LX, Chen C, Yan X et al (2019) Resveratrol attenuates pressure overload-induced cardiac fibrosis and diastolic dysfunction via PTEN\/AKT\/Smad2\/3 and NF-\u03baB signaling pathways. Mol Nutr Food Res. https:\/\/doi.org\/10.1002\/mnfr.201900418","journal-title":"Mol Nutr Food Res"},{"key":"3777_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116748","author":"P Guan","year":"2019","unstructured":"Guan P, Sun ZM, Wang N et al (2019) Resveratrol prevents chronic intermittent hypoxia-induced cardiac hypertrophy by targeting the PI3K\/AKT\/mTOR pathway. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2019.116748","journal-title":"Life Sci"},{"key":"3777_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.redox.2018.10.021","volume":"20","author":"C Chen","year":"2019","unstructured":"Chen C, Zou LX, Lin QY et al (2019) Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload. Redox Biol 20:390\u2013401. https:\/\/doi.org\/10.1016\/j.redox.2018.10.021","journal-title":"Redox Biol"},{"key":"3777_CR27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"3777_CR28","unstructured":"Cardiovascular diseases. https:\/\/www.who.int\/health-topics\/cardiovascular-diseases\/#tab=tab_1. Accessed 18 Feb 2020"},{"key":"3777_CR29","first-page":"1624","volume":"10","author":"CE Ong","year":"2017","unstructured":"Ong CE, Pan Y, Mak JW (2017) The roles of cytochromes P450 in vascular biology and cardiovascular homeostasis. Int J Clin Exp Med 10:1624\u20131636","journal-title":"Int J Clin Exp Med"},{"key":"3777_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.pharmthera.2005.05.011","volume":"112","author":"RH Elbekai","year":"2006","unstructured":"Elbekai RH, El-Kadi AOS (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564\u2013587","journal-title":"Pharmacol Ther"},{"key":"3777_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.prostaglandins.2011.12.003","volume":"98","author":"KU Malik","year":"2012","unstructured":"Malik KU, Jennings BL, Yaghini FA et al (2012) Contribution of cytochrome P450 1B1 to hypertension and associated pathophysiology: a novel target for antihypertensive agents. Prostaglandins Other Lipid Mediat 98:69\u201374","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"3777_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00204-015-1620-8","volume":"90","author":"ZH Maayah","year":"2016","unstructured":"Maayah ZH, El-Kadi AOS (2016) The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy. Arch Toxicol 90:119\u2013136","journal-title":"Arch Toxicol"},{"key":"3777_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.mayocpiqo.2019.05.001","volume":"3","author":"VA Pallazola","year":"2019","unstructured":"Pallazola VA, Davis DM, Whelton SP et al (2019) A clinician\u2019s guide to healthy eating for cardiovascular disease prevention. Mayo Clin Proc Innov Qual Outcomes 3:251\u2013267. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2019.05.001","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"3777_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009874.pub2","author":"L Hartley","year":"2013","unstructured":"Hartley L, Igbinedion E, Holmes J et al (2013) Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD009874.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3777_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2010.08.010","volume":"299","author":"L MacPherson","year":"2010","unstructured":"MacPherson L, Matthews J (2010) Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor \u03b1 expression in human breast cancer cells. Cancer Lett 299:119\u2013129. https:\/\/doi.org\/10.1016\/j.canlet.2010.08.010","journal-title":"Cancer Lett"},{"key":"3777_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12263-007-0069-7","volume":"2","author":"JT Hwang","year":"2008","unstructured":"Hwang JT, Kwon DY, Park OJ, Kim MS (2008) Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2:323\u2013326. https:\/\/doi.org\/10.1007\/s12263-007-0069-7","journal-title":"Genes Nutr"},{"key":"3777_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/emm.2007.25","volume":"39","author":"EP Chang","year":"2007","unstructured":"Chang EP, Kim MJ, Jong HL et al (2007) Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 39:222\u2013229. https:\/\/doi.org\/10.1038\/emm.2007.25","journal-title":"Exp Mol Med"},{"key":"3777_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10565-015-9308-7","volume":"31","author":"ZH Maayah","year":"2015","unstructured":"Maayah ZH, Abdelhamid G, El-Kadi AOS (2015) Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-\u03baB. Cell Biol Toxicol 31:241\u2013259. https:\/\/doi.org\/10.1007\/s10565-015-9308-7","journal-title":"Cell Biol Toxicol"},{"key":"3777_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.03.016","author":"AH Alammari","year":"2020","unstructured":"Alammari AH, Shoieb SM, Maayah ZH, El-Kadi AOS (2020) Fluconazole represses cytochrome P450 1B1 and its associated arachidonic acid metabolites in the heart and protects against angiotensin II-induced cardiac hypertrophy. J Pharm Sci. https:\/\/doi.org\/10.1016\/j.xphs.2020.03.016","journal-title":"J Pharm Sci"},{"key":"3777_CR40","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1159\/000369747","volume":"35","author":"HP Qi","year":"2015","unstructured":"Qi HP, Wang Y, Zhang QH et al (2015) Activation of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) through NF-\u03baB\/brg1 and TGF-\u03b2 1 pathways attenuates cardiac remodeling in pressure-overloaded rat hearts. Cell Physiol Biochem 35:899\u2013912. https:\/\/doi.org\/10.1159\/000369747","journal-title":"Cell Physiol Biochem"},{"key":"3777_CR41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1139\/y06-043","volume":"84","author":"B Wang","year":"2006","unstructured":"Wang B, Ouyang J, Xia Z (2006) Effects of triiodo-thyronine on angiotensin-induced cardiomyocyte hypertrophy: reversal of increased beta-myosin heavy chain gene expression. Can J Physiol Pharmacol 84:935\u2013941","journal-title":"Can J Physiol Pharmacol"},{"key":"3777_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1161\/01.RES.72.4.857","volume":"72","author":"C Chassagne","year":"1993","unstructured":"Chassagne C, Wisnewsky C, Schwartz K (1993) Antithetical accumulation of myosin heavy chain but not \u03b1-actin mRNA isoforms during early stages of pressure-overload-induced rat cardiac hypertrophy. Circ Res 72:857\u2013864. https:\/\/doi.org\/10.1161\/01.RES.72.4.857","journal-title":"Circ Res"},{"key":"3777_CR43","doi-asserted-by":"publisher","first-page":"H1446","DOI":"10.1152\/ajpheart.00274.2002","volume":"283","author":"NR Alpert","year":"2002","unstructured":"Alpert NR, Brosseau C, Federico A et al (2002) Molecular mechanics of mouse cardiac myosin isoforms. Am J Physiol - Hear Circ Physiol 283:H1446\u2013H1454. https:\/\/doi.org\/10.1152\/ajpheart.00274.2002","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"3777_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.yjmcc.2007.07.045","volume":"43","author":"MP Gupta","year":"2007","unstructured":"Gupta MP (2007) Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 43:388\u2013403","journal-title":"J Mol Cell Cardiol"},{"key":"3777_CR45","first-page":"80","volume":"7","author":"G Kessler-Icekson","year":"2002","unstructured":"Kessler-Icekson G, Barhum Y, Schaper J et al (2002) ANP expression in the hypertensive heart. Exp Clin Cardiol 7:80\u201384","journal-title":"Exp Clin Cardiol"},{"key":"3777_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11010-017-2943-y","volume":"429","author":"ZH Maayah","year":"2017","unstructured":"Maayah ZH, Althurwi HN, El-Sherbeni AA et al (2017) The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol. Mol Cell Biochem 429:151\u2013165. https:\/\/doi.org\/10.1007\/s11010-017-2943-y","journal-title":"Mol Cell Biochem"},{"key":"3777_CR47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.bcp.2013.11.015","volume":"87","author":"AA El-Sherbeni","year":"2014","unstructured":"El-Sherbeni AA, El-Kadi AOS (2014) Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy. Biochem Pharmacol 87:456\u2013466. https:\/\/doi.org\/10.1016\/j.bcp.2013.11.015","journal-title":"Biochem Pharmacol"},{"key":"3777_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12967-014-0323-x","volume":"12","author":"Q Dong","year":"2014","unstructured":"Dong Q, Wu Z, Li X et al (2014) Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca2+ cycling proteins. J Transl Med 12:323. https:\/\/doi.org\/10.1186\/s12967-014-0323-x","journal-title":"J Transl Med"},{"key":"3777_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/CH-2011-1424","volume":"50","author":"K Magyar","year":"2012","unstructured":"Magyar K, Halmosi R, Palfi A et al (2012) Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 50:179\u2013187. https:\/\/doi.org\/10.3233\/CH-2011-1424","journal-title":"Clin Hemorheol Microcirc"},{"key":"3777_CR50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/toxsci\/kfy206","volume":"166","author":"J Ghosh","year":"2018","unstructured":"Ghosh J, Chowdhury AR, Srinivasan S et al (2018) Cigarette smoke toxins-induced mitochondrial dysfunction and pancreatitis involves aryl hydrocarbon receptor mediated Cyp1 gene expression: protective effects of resveratrol. Toxicol Sci 166:428\u2013440. https:\/\/doi.org\/10.1093\/toxsci\/kfy206","journal-title":"Toxicol Sci"},{"key":"3777_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10637-018-0622-9","volume":"37","author":"AC Huderson","year":"2019","unstructured":"Huderson AC, Rekha Devi PV, Niaz MS et al (2019) Alteration of benzo(a)pyrene biotransformation by resveratrol in Apc Min\/+ mouse model of colon carcinogenesis. Invest New Drugs 37:238\u2013251. https:\/\/doi.org\/10.1007\/s10637-018-0622-9","journal-title":"Invest New Drugs"},{"key":"3777_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1006\/bbrc.1999.1152","volume":"262","author":"YJ Chun","year":"1999","unstructured":"Chun YJ, Kim MY, Guengerich FP (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262:20\u201324. https:\/\/doi.org\/10.1006\/bbrc.1999.1152","journal-title":"Biochem Biophys Res Commun"},{"key":"3777_CR53","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1021\/acs.molpharmaceut.5b00873","volume":"13","author":"AA El-Sherbeni","year":"2016","unstructured":"El-Sherbeni AA, El-Kadi AOS (2016) Repurposing resveratrol and fluconazole to modulate human cytochrome P450-mediated arachidonic acid metabolism. Mol Pharm 13:1278\u20131288. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00873","journal-title":"Mol Pharm"},{"key":"3777_CR54","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00204-014-1419-z","volume":"90","author":"ZH Maayah","year":"2016","unstructured":"Maayah ZH, El-Kadi AOS (2016) 5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-\u03baB-dependent mechanism. Arch Toxicol 90:359\u2013373. https:\/\/doi.org\/10.1007\/s00204-014-1419-z","journal-title":"Arch Toxicol"},{"key":"3777_CR55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/jcp.24443","volume":"229","author":"L Zhang","year":"2014","unstructured":"Zhang L, Li Y, Chen M et al (2014) 15-LO\/15-HETE mediated vascular adventitia fibrosis via p38 MAPK-dependent TGF-\u03b2. J Cell Physiol 229:245\u2013257. https:\/\/doi.org\/10.1002\/jcp.24443","journal-title":"J Cell Physiol"},{"key":"3777_CR56","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1476-5381.2011.01321.x","volume":"163","author":"M Revermann","year":"2011","unstructured":"Revermann M, Mieth A, Popescu L et al (2011) A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm. Br J Pharmacol 163:1721\u20131732. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01321.x","journal-title":"Br J Pharmacol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-020-03777-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:42:37Z","timestamp":1744177357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-020-03777-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":56,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3777"],"URL":"https:\/\/doi.org\/10.1007\/s11010-020-03777-9","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}